Avinger, a manufacturer of multi-functional catheters for treating patients with peripheral artery disease (PAD), has completed enrollment in CONNECT (Chronic TOtal OcclusioN CrossiNg with thE WildCat CatheTer) clinical trial.
The CONNECT trial is a prospective, multi-center, non-randomized study to evaluate Wildcat Catheter’s ability to cross chronic total occlusions in femoropopliteal lesions which is the leading cause of amputations associated with PAD in the US.
Avinger’s Wildcat Catheter received FDA 510(k) clearance in February 2009 for use as a guidewire support device to access discreet areas of the vasculature.
Avinger conducted the study to secure FDA clearance for an indication specific to crossing CTOs.